2022
DOI: 10.1128/aac.01834-21
|View full text |Cite
|
Sign up to set email alerts
|

Bloodstream Infections Caused by Magnusiomyces capitatus and Magnusiomyces clavatus : Epidemiological, Clinical, and Microbiological Features of Two Emerging Yeast Species

Abstract: Background: Magnusiomyces clavatus and Magnusiomyces capitatus are emerging yeasts with intrinsic resistance to many commonly used antifungal agents. Identification is difficult, and determination of susceptibility patterns with commercial and reference methods is equally challenging. For this reason, few data on invasive infections by Magnusiomyces spp. are available. Objectives: To determine the epidemio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 33 publications
(55 reference statements)
1
5
0
Order By: Relevance
“…In this report, S. clavata was found to be responsible for disseminated and life-threatening infection in a young patient with AML, during a profound neutropenic phase after the second course of the FLAI CHT regimen. In line with available literature ( 10 , 12 , 22 , 23 ), the susceptibility test has shown a high MIC for echinocandins and fluconazole and low for amphotericin B, itraconazole, posaconazole, and voriconazole ( 10 , 12 , 23 25 ). Not enough clinical data are available to assess the optimal treatment for this infection: a 2014 guideline for treatment of S. clavata infection recommended any formulation of amphotericin B ± other antifungals as the preferred approach ( 12 , 22 ).…”
Section: Discussionsupporting
confidence: 72%
“…In this report, S. clavata was found to be responsible for disseminated and life-threatening infection in a young patient with AML, during a profound neutropenic phase after the second course of the FLAI CHT regimen. In line with available literature ( 10 , 12 , 22 , 23 ), the susceptibility test has shown a high MIC for echinocandins and fluconazole and low for amphotericin B, itraconazole, posaconazole, and voriconazole ( 10 , 12 , 23 25 ). Not enough clinical data are available to assess the optimal treatment for this infection: a 2014 guideline for treatment of S. clavata infection recommended any formulation of amphotericin B ± other antifungals as the preferred approach ( 12 , 22 ).…”
Section: Discussionsupporting
confidence: 72%
“…1,2 Closely related to, and potentially misidentified as, Magnusiomyces capitatus, its incidence has likely been underestimated prior to use of advanced identification techniques. 3,4 Detailed ecological studies are scarce but other Magnusiomyces spp are ubiquitous in environmental sources such as water, soil, and plants. 5 In one study of hospitalized adults, asymptomatic colonization with Magnusiomyces spp was relatively common, especially in the respiratory tract, and associated with invasive infection in immunocompromised individuals.…”
Section: Disseminated Fungal Disease Caused By Magnusiomyces Clavatus...mentioning
confidence: 99%
“…Hospital-associated outbreaks have also been reported with the largest involving 39 cases in France in 2013 [ 71 ]. Thirty-four cases of BSI have been reported from Germany and Austria over 20 years, though various sporadic cases have also been reported [ 72 ]. Infection is primarily seen in immunocompromised individuals especially those with acute leukemia.…”
Section: Introductionmentioning
confidence: 99%
“…[ 69 ]. The natural reservoirs and virulence factors of these yeasts are not known, and the whole genome sequencing of the agent suggest its recent emergence [ 72 ].…”
Section: Introductionmentioning
confidence: 99%